The US Food and Drug Administration (FDA) has granted fast track designation to Moderna’s Covid-19 vaccine candidate, mRNA-1273.

This designation will expedite future reviews of the vaccine as it progresses into later-stage clinical trials. Moderna’s Covid-19 vaccine is currently in Phase I clinical trials, however, the FDA recently authorised the company to conduct a Phase II trial.

The company’s chief medical officer commented: “Fast track designation underscores the urgent need for a vaccine against the novel coronavirus.

“As we await the full set of clinical data from the NIAID-led Phase 1 study, we are actively preparing for our Phase II and Phase III clinical studies to continue learning about the potential of mRNA-1273 to protect against SARS-CoV-2,” the virus that causes Covid-19.

Moderna has received funding from BARDA and CEPI to date to support its accelerated Covid-19 vaccine development programme.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.